Genomic Health, Inc.

Nsabp Foundation, Inc.

Bristol-Myers Squibb Compnay

Rush-Presbyterian-St. Luke's Medical Center

Instituto Nazionale Tumori

Nsabp Foundations, Inc.

Rush University Medical Center

Aventisub Ii Inc.

Fondazione Irccs Istituto Nazionale Dei Tumori

Aventis Corporation Gmbh

Joffre B Baker

Steven Shak

Soonmyung Paik

Wayne Cowens

Michael C Kiefer

James Hackett

Maureen T Cronin

Drew Watson

Steve Shak

John L Bryant

Kim Clark

Tara Maddala

Melody A Cobleigh

Audrey Goddard

Michael Graham Walker

Frederick L Baehner

Dejan Knezevic

Luca Gianni

Francois Collin

Kim Langone

Jose Baselga

Mei-Lan Liu

Randal W Scott

Michael R Crager

Mark Lee

Kunbin Qu

Robert J Pelham

Diana Cherbavaz

John Morlan

Shirin K Ford

Dominick V Sinicropi

Randy Scott

David J Mauro

Kim Clark-Langane

James C Stephans

Carl Yoshizawa

Robert Pelham

Robert Gray

The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.

Method to use gene expression to determine likelihood of clinical outcome of renal cancer

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.

Gene expression markers for breast cancer prognosis

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.

Prediction of likelihood of cancer recurrence

The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.

Method for using gene expression to determine prognosis of prostate cancer

The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.

Gene expression profiling in biopsied tumor tissues

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.

Gene expression markers for predicting response to chemotherapy

The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

Genes involved in estrogen metabolism

The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.

Predicting response to chemotherapy using gene expression markers

The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

Gene expression markers for prediction of patient response to chemotherapy

Growing community of inventors

Montara, CA, United States of America

Joffre B Baker